Introduction

In a groundbreaking development for the field of hepatology, HepQuant, LLC has unveiled HepQuant DuO™, a revolutionary quantitative liver function test aimed at significantly enhancing the management of patients suffering from liver disease.

Overview of HepQuant DuO

This minimally invasive blood test allows liver specialists to effectively measure liver function as well as portal-systemic shunting, which are crucial indicators of liver health, particularly in patients grappling with conditions like esophageal varices, portal hypertension, and cirrhosis.

Features of the Test

The HepQuant DuO test, which is a Laboratory Developed Test (LDT), is designed to provide actionable insights that support liver specialists in making informed clinical decisions.

The test outcomes include the Disease Severity Index (DSI) risk score, SHUNT% for evaluating portal systemic shunting, and Hepatic Reserve (HR) values that help patients comprehend the implications of their liver impairment.

Prevalence of Liver Disease

This initiative is particularly timely as the American Liver Foundation estimates that over 10% of Americans already live with liver disease, with an additional 130 million at risk for various liver-related ailments ranging from non-alcoholic fatty liver disease to autoimmune conditions.

Testing Procedure

The procedure for the HepQuant DuO testing is straightforward and minimally invasive, requiring only two blood samples taken after the patient drinks a specified beverage.

Integration with Clinical Evaluations

The rapid integration of test results with existing clinical evaluations enables physicians to better assess disease severity and predict potential complications, such as ascites, encephalopathy, and variceal bleeding.

Clinical Research and Presentations

HepQuant has placed a strong emphasis on substantiating the clinical utility of the HepQuant DuO through extensive research.

With six abstracts set to be featured at The Liver Meeting 2024, three of which have been acknowledged with the prestigious Poster of Distinction, the company is at the forefront of disseminating knowledge on liver disease management.

Expert Commentary

Dr. Buck Patel, a gastroenterologist from Peak Gastro Associates in Colorado Springs, remarked on the transformative impact of the HepQuant DuO test on patient consultations.

Conclusion

The introduction of HepQuant DuO represents a significant advancement in the fight against liver disease, consistently reinforcing HepQuant’s commitment to providing exceptional diagnostic tools.

Their innovations promise to enhance patient outcomes by offering more precise measures of liver function, informing personalized treatment plans and fostering better patient-physician communication.

As more healthcare providers adopt this new tool, the hope is that patients with liver disease will experience quicker diagnoses, better risk assessments, and ultimately, enhanced quality of life.

Additional Information

For additional information about HepQuant DuO and its clinical implications, please visit [HepQuant.com](https://hepquant.com).